spawns Amylyx Pharmaceuticals (NASDAQ:AMLX) traded sharply higher on Wednesday after the drug developer announced the acquisition of avexitide, a GLP-1 receptor antagonist developed by Eiger BioPharmaceuticals (OTC:EIGRQ). The transaction was completed on July 9 after Amylyx (AMLX) emerged as the winning bidder in an auction held to sell Avexitide underContinue Reading
A new study has linked the use of GLP-1 drugs and metformin to a lower risk of developing certain obesity-related cancers in patients with Type 2 diabetes. The study, which was published Friday on the JAMA Network Open website, showed that patients taking GLP-1 drugs or metformin showed a significantlyContinue Reading
Suriyawut Suriya/iStock via Getty Images Taking Novo Nordisk’s older GLP-1 medication Saxenda (liraglutide) while regularly exercising led to maintaining bone mineral density (BMD) while losing weight, according to a new study. Researchers conducted a secondary analysis of a randomized clinical trial of 195 obese adults. Results showed that exercise andContinue Reading
Devonyu A new peer-reviewed study suggested this week that GLP-1 drugs, popularly used for weight loss, are associated with a lower risk of dementia in older people with diabetes. The trial considered real-world data from Sweden using more than 88,000 patients aged 65 or older with type 2 diabetes mellitusContinue Reading
phototechno Amylyx Pharmaceuticals (NASDAQ:AMLX) has signed an agreement with Eiger BioPharmaceuticals (OTC:EIGRQ) to acquire the rights to the latter’s Phase 3-ready GLP-1 receptor antagonist, Avexitide. Cambridge, Massachusetts-based Amylyx (AMLX) has agreed to pay $35.1M plus other payments for the acquisition, the company announced in an SEC filing late Friday. TheContinue Reading
